Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, +1432

The Lancet

Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseHealth PolicyCardiovascular Outcomes +7

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, +1434

The Lancet

Metabolic SyndromeDiabetes ManagementUrologyChronic Kidney DiseaseDiabetes +8

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

Séverine Vermeire, Stefan Schreiber, Robert Petryka, +12

The Lancet

Fitzroy StudyGastroenterologyClinical GastroenterologyUlcerative ColitisPhase 2 +2

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

Brian G. Feagan, Bruce E. Sands, William J. Sandborn, +54

˜The œLancet. Gastroenterology & hepatology

Systemic TreatmentGolimumab MonotherapyGastroenterologyPathologyUlcerative Colitis +2

A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease

Satish Keshav, Tomáš Vaňásek, Yaron Niv, +12

PLoS ONE

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Laurent Peyrin‐Biroulet, Ailsa Hart, Peter Bossuyt, +323

˜The œLancet. Gastroenterology & hepatology

InflammationAnti-inflammatoryImmunologyGastroenterologyMaintenance Therapy +5

Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis

Raja Atreya, Stuart Bloom, Franco Scaldaferri, +14

Journal of Crohn s and Colitis

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Silvio Danese, Remo Panaccione, Brian G. Feagan, +137

˜The œLancet. Gastroenterology & hepatology

UrologyMoxibustionGastroenterologyDouble-blind Galaxi-1 TrialMaintenance Results +4

Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled trial

Matthieu Allez, Brett E. Skolnick, Maria Wiśniewska‐Jarosińska, +2

Gut

Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn’s Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study

William J. Sandborn, Paul Rutgeerts, Jean–Frédéric Colombel, +5

Journal of Crohn s and Colitis